California molecular diagnostics maker CardioDx takes another swing at an initial public offering and adds a few members to its leadership team. More than 5 months after ditching efforts to open on public markets, California-based CardioDx is ready to take another swing at an initial public offering. In regulatory documents filed this week the molecular diagnostics maker assigned new underwriters, named a couple of new executives and added 2 members to its board of directors.
Help employers find you! Check out all the jobs and post your resume.
